EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities by Yedier-Bayram, O, Gokbayrak, B, Kayabolen, A, Aksu, AC, Cavga, AD, Cingöz, A, Kala, EY, Karabiyik, G, Günsay, R, Esin, B, Morova, T, Uyulur, F, Syed, H, Philpott, M, Cribbs, AP, Kung, SHY, Lack, NA, Onder, TT, Bagci-Onder, T

Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival by Ozyerli-Goknar, E, Kala, EY, Aksu, AC, Bulut, I, Cingöz, A, Nizamuddin, S, Biniossek, M, Seker-Polat, F, Morova, T, Aztekin, C, Kung, SHY, Syed, H, Tuncbag, N, Gönen, M, Philpott, M, Cribbs, AP, Acilan, C, Lack, NA, Onder, TT, Timmers, HTM, Bagci-Onder, T